Chronic lymphocytic leukemia: New concepts for future therapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 5, 2010, Pages 369-378

  Wierda, William ^a   Chiorazzi, Nicholas ^b   Dearden, Claire ^c   Brown, Jennifer ^d   Montserrat, Emili ^e   Shpall, Elizabeth ^a   Stilgenbauer, Stephan ^f   Muneer, Sabeeha ^g   Grever, Michael ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF ULM   (Germany)

^g Physicians' Education Resource   (United States)

^h OHIO STATE UNIVERSITY   (United States)

Author keywords

Alemtuzumab; Bendamustine; Flavopiridol; Lenalidomide; Ofatumumab

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; ALLOPURINOL; APRIL PROTEIN; B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; CHEMOKINE RECEPTOR CXCR4; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; LUMILIXIMAB; OBATOCLAX; OBINUTUZUMAB; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PLERIXAFOR; PREDNISONE; PROTEIN P53; RITUXIMAB; SMALL MOLECULE TRANSPORT AGENT; TUMOR NECROSIS FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ATAXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; CELL SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOGENETICS; CYTOPENIA; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DONOR; DRUG DOSE ESCALATION; DYSPNEA; EUPHORIA; FATIGUE; GENE EXPRESSION PROFILING; GENETIC RISK; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; T CELL DEPLETION; TREATMENT DURATION; TREATMENT FREE SURVIVAL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VOMITING; IMMUNOTHERAPY; INSTRUMENTATION; METHODOLOGY; MOLECULARLY TARGETED THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79952277727     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.070     Document Type: Review

References (95)

1. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55:188-96. (Pubitemid 41682591)
2. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35:118-27. (Pubitemid 20152978)
3. Elsner J, Hochstetter R, Spiekermann K, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996; 88:4684-93. (Pubitemid 26419153)
4. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 2009; 9:365-70.
5. Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 2009; 114:3052-5.
6. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008; 14:178-83.
7. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164-74.
8. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756-65.
9. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000; 4:5-21. (Pubitemid 34947476)
10. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352:804-15.
11. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115:755-64. (Pubitemid 40322252)
12. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625-38. (Pubitemid 33126813)
13. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639-47. (Pubitemid 33126814)
14. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7:591-600. (Pubitemid 40796982)
15. Baskar S, Kwong KY, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14:396-404. (Pubitemid 351226106)
16. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007; 109:259-70. (Pubitemid 46070124)
17. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111:1524-33. (Pubitemid 351213442)
18. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005; 106:1824-30. (Pubitemid 41208600)
19. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007; 137:288-96. (Pubitemid 46650259)
20. Longo PG, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111:846-55.
21. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002; 100:3741-8. (Pubitemid 35303946)
22. Marone R, Cmiljanovic V, Giese B, et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
23. Niedermeier M, Hennessy BT, Knight ZA, et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113:5549-57.
24. Flinn I, Byrd J, Furman R, et al. Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110 isoform-selective inhibitor of phosphatidylinositol 3-Kinase, in patients with relapsed or refractory B-cell malignancies. Blood 2009; 114: (abstract 922).
25. Clinical trials.gov [Web site]. A phase I study to investigate the safety and clinical activity of CAL-101 in combination with bendamustine and rituximab in patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT01088048. Accessed: April 16, 2010.
26. Haiat S, Billard C, Quiney C, et al. Role of BAFF and APRIL in human B-cell hronic lymphocytic leukaemia. Immunology 2006; 118:281-92.
27. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007; 109:703-10. (Pubitemid 46105972)
28. Kofler DM, Gawlik BB, Elter T, et al. Final results of a phase Ib trial of atacicept to neutralize APRIL and BLyS in patients with refractory or relapsed chronic lymphocytic leukemia (CLL). Blood 2009; 114:937 (abstract 2373).
29. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22:211-9.
30. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580-9.
31. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15:995-1004.
32. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56.
33. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112:3322-9.
34. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100:1177-84. (Pubitemid 34864269)
35. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23:117-24.
36. Gonzalez D, Martinez P, Wade R, et al. Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion. Blood 2008; 112: (abstract 784).
37. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114:2589-97.
38. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111:5291-7.
39. Chanan-Khan A, Czuczman M, Padmanabhan S, et al.. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. Blood 2007; 110: (abstract 3108).
40. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:5343-9. (Pubitemid 46623164)
41. Lin TS, Heerema NA, Lozanski G, et al.. Flavopiridol (alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. Blood 2008; 112: (abstract 46).
42. Schaffner C, Stilgenbauer S, Rappold GA, et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94:748-53. (Pubitemid 29323889)
43. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98:814-22.
44. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113:3801-8.
45. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749-55.
46. Wierda W, Kipps T, Durig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood 2009; 114:90 (abstract 207).
47. Clinicaltrials.gov [Web site]. Ofatumumab added to fludarabine- cyclophosphamide vs. fludarabine-cyclophosphamide combination in relapsed subjects with chronic lymphocytic leukemia. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00824265. Accessed: September 7, 2010.
48. Clinical trials.gov [Web site]. Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01039376. Accessed: April 7, 2010.
49. Clinicaltrials.gov [Web site]. Ofatumumab + chlorambucil vs. chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT 1). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00748189. Accessed: April 7, 2010.
50. Clinicaltrials.gov [Web site]. Ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B-cell non-hodgkin's lymphoma (NHL) unresponsive to rituximab or a rituximab-containing regimen (COMPLEMENT A+B). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01077518. Accessed: March 29, 2010.
51. Clinicaltrials.gov [Web site]. Ofatumumab and bendamustine for previously treated chronic lymphocytic leukemia (CLL). Available at: http://www. clinicaltrials.gov/ct2/show/NCT01010568. Accessed: April 6, 2010.
52. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-02.
53. Morschhauser F, Cartron G, Lamy T, et al. Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood 2009; 114:364 (abstract 884).
54. Clinicaltrials.gov [Web site]. An open-label, multi-center, three arm randomized study to investigate the safety and efficacy on progression-free survival of RO5072759 + chlorambucil (GClb) compared to rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities. Available at: http://clinicaltrials.gov/ct2/show/NCT01010061. Accessed: July 7, 2010.
55. Byrd JC, O'Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13:4448-55. (Pubitemid 47219713)
56. Fournier S, Delespesse G, Rubio M, et al. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992; 89:1312-21.
57. Pathan NI, Chu P, Hariharan K, et al. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008; 111:1594-602. (Pubitemid 351213450)
58. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 115:489-95.
59. Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) versus FCR alone in subjects with relapsed chronic lymphocytic leukemia (CLL) (LUCID). Clinical trials.gov [website] Available at http://www.clinicaltrials. gov/ct2/show/NCT00391066. Accessed: March 29, 2010.
60. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378-84.
61. Rummel MJ, Nierderle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:168 (abstract 405).
62. Fischer K, Stilgenbauer S, Schweighofer C, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008; 112: (abstract 330).
63. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009; 114:89 (abstract 205).
64. Clinical trials.gov [Web site]. Phase III trial of combined immunochemotherapy with fludarabine. cyclophosphamide and rituximab (FCR) versus bendamustine and rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00769522. Accessed: February 12, 2009.
65. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405-11. (Pubitemid 46105933)
66. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006; 24:1575-81. (Pubitemid 46638781)
67. Reynolds C, Di Bella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-Cell chronic lymphocytic leukemia. Blood 2008; 112: (abstract 327).
68. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109:2291-8. (Pubitemid 46801560)
69. O'Brien S, Gribben J, Cousin T, et al. 5-year follow-up of heavily pretreated patients with relapsed/refractory CLL in phase 3 study: significant survival benefit with oblimersen plus fludarabine/cyclophosphamide in responding patients. Haematologica 2009; 94(suppl 2):141 (abstract 357).
70. O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27:5208-12.
71. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113:299-305.
72. Clinical trials.gov [Web site]. Obatoclax, fludarabine, and rituximab in treating patients with previously treated chronic lymphocytic leukemia. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00612612. Accessed: March 29, 2010.
73. Roberts AW, Seymour JF, Brown JR, et al. An Ongoing phase 1/2a study of ABT-263; pharmacokinetics (PK), safety and anti-tumor activity in patients (pts) with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2009; 114:364 (abstract 883).
74. Clinicaltrials.gov [Web site]. A study of ABT-263 in combination with rituximab in previously untreated patients with B-cell, chronic lymphocytic leukemia (CLL). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01087151. Accessed: March 29, 2010.
75. Clinicaltrials.gov [Web site]. Study of ABT-263 when administered in combination with either fludarabine/cyclophosphamide/rituximab or bendamustine/rituximab in relapsed or refractory chronic lymphocytic leukemia. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00868413. Accessed: March 29, 2010.
76. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83. (Pubitemid 46628473)
77. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92:3804-16. (Pubitemid 28525207)
78. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infection of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005; 11:4176-81. (Pubitemid 40791583)
79. Chen C, Paul H, Xu W, et al. A Phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood 2008; 112: (abstract 44).
80. Ferrajoli A, O'Brien S, Wierda W, et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 2008; 112: (abstract 45).
81. Ferrajoli A, Badoux X, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009; 114:89 (abstract 206).
82. Clinicaltrials.gov [Web site]. A study to evaluate the efficacy and safety of lenalidomide as maintenance therapy for patients with B-cell CLL following second line therapy (THE CONTINUUM TRIAL). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00774345. Accessed: April 16, 2010.
83. Clinicaltrials.gov [Web site]. Study of bendamustine/rituxan induction chemotherapy with revlimid maintenance for relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00974233. Accessed: April 16, 2010.
84. Michallet M, Dreger P, Sutton LM, et al. Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch. Blood 2009; 114: (abstract 877).
85. Milligan DW, Fernandes S, Dasgupta R, et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105:397-404. (Pubitemid 40053111)
86. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21:12-7. (Pubitemid 44921829)
87. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008; 26:5094-100.
88. Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111:446-52.
89. Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137:355-63. (Pubitemid 46650260)
90. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27:3994-4001.
91. Pettitt A, Matutes E, Dearden C, et al. Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Paper presented at: The 14th Congress of the European Hematology Association; June 4-7, 2009; Berlin, Germany. Abstract 0351.
92. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554-61. (Pubitemid 34534522)
93. Lepretre S, Aurran T, Mahe B, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the Groupe Ouest-Est dEtudes Des Leucémies Aiges Et Autres Maladies Du sang(GOELAMS): CLL2007FMP (for fit medically patients). Blood 2009; 114:225 (abstract 538).
94. Engert A, Gercheva L, Robak T, et al. Improved progression-free survival (PFS) of alemtuzumab (Campath®, MabCampath®) plus fludarabine (Fludara®) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial. Blood 2009; 114:224 (abstract 537).
95. Elter T, James R, Stilgenbauer S, et al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L Trial of the German CLL Study Group. Blood 2009; 114:92 (abstract 209)